CTRI/2018/01/011142已完成3 期
A Randomized Comparative, Open Label, 2 Arm, Phase III Clinical Study to Evaluate the Safety and Efficacy of Vaginal Lubricant for Improvement of Vaginal Dryness
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Women with active sex lives of at least one sexual intercourse in a week
- •Women without a history of sensitivity to similar formulations
- •Subjects willing to sign informed consent and follow the study procedure.
排除标准
- •Women using other intra vaginal gel moisturizer, diagnosed with cancer, Women using hormone replacement therapy in the last 3 months, Absence of history or visible evidence of chronic skin disease or regional infections, genital herpes, vaginal infections or urinary tract infection, Pregnant or lactating, women likely to become pregnant, Personal history of allergy and hypersensitivity to any product of feminine hygiene, severe systemic complications of viral infections, severe systemic illness like cardiovascular disorders, neurological disorders, renal disorders, autoimmune disorders,Not willing to sign informed consent form
研究者
相似试验
已完成
3 期
To compare the efficacy and safety of Diclofenac 25 mg + paracetamol 325 mg FDC vs. Aceclofenac 100mg in the management of osteoarthritisCTRI/2010/091/000076Troikaa Pharmaceuticals Limited150
已完成
4 期
To compare the efficacy and safety of Oral Trans-Mucosal Fentanyl Citrate vs. oral morphine in patients with break through cancer pain.CTRI/2010/091/001179Troikaa Pharmaceuticals Limited200
进行中（未招募）
1 期
A Phase II, Open-Label, Randomised, Comparative, International Multicentre Study to Assess the Safety and Efficacy of Three Different Doses of AZD2281 Given Orally Once or Twice Daily and Intravenous Liposomal Doxorubicin Given Monthly in Patients With Advanced BRCA1- or BRCA2-Associated Ovarian Cancer Who Have Failed Previous Platinum-Based Chemotherapy Estudio de fase II, abierto, aleatorizado, comparativo, internacional y multicéntrico para evaluar la seguridad y la eficacia de tres dosis diferentes de AZD2281 administradas por vía oral una o dos veces al día y doxorrubicina liposomal intravenosa administrada mensualmente en pacientes con cáncer de ovario avanzado asociado a BRCA1 o BRCA2 en las que ha fracasado una quimioterapia previa basada en platinoEUCTR2007-007622-22-ESAstraZeneca AB97
进行中（未招募）
1 期
A Phase II, Open-Label, Randomised, Comparative, International Multicentre Study to Compare the Safety and Efficacy of Two Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Liposomal Doxorubicin Given Monthly in Patients With Advanced BRCA1- or BRCA2-Associated Ovarian Cancer Who Have Failed Previous Platinum-Based ChemotherapyEUCTR2007-007622-22-DEAstraZeneca AB90
进行中（未招募）
不适用
Olaparib in combination with carboplatin and paclitaxel in patients with advanced ovarian cancerSerous ovarian cancerMedDRA version: 16.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-015970-36-DEAstraZeneca AB150